ETF Managers Group’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
---|---|---|---|---|---|---|---|---|
2023
Q1 | $2.08M | Sell |
10,382
-742
| -7% | -$149K | 0.07% | 150 |
|
2022
Q4 | $2.64M | Sell |
11,124
-90
| -0.8% | -$21.4K | 0.12% | 97 |
|
2022
Q3 | $2.25M | Sell |
11,214
-23,965
| -68% | -$4.8M | 0.07% | 145 |
|
2022
Q2 | $5.12M | Buy |
35,179
+18,279
| +108% | +$2.66M | 0.15% | 126 |
|
2022
Q1 | $2.79M | Sell |
16,900
-5,379
| -24% | -$889K | 0.06% | 177 |
|
2021
Q4 | $3.81M | Sell |
22,279
-3,423
| -13% | -$585K | 0.08% | 176 |
|
2021
Q3 | $4.56M | Buy |
25,702
+6,822
| +36% | +$1.21M | 0.09% | 154 |
|
2021
Q2 | $3.13M | Sell |
18,880
-7,892
| -29% | -$1.31M | 0.05% | 186 |
|
2021
Q1 | $3.62M | Buy |
26,772
+7,069
| +36% | +$955K | 0.06% | 153 |
|
2020
Q4 | $2.58M | Buy |
19,703
+1,380
| +8% | +$181K | 0.06% | 174 |
|
2020
Q3 | $2.66M | Buy |
18,323
+7,966
| +77% | +$1.16M | 0.08% | 142 |
|
2020
Q2 | $1.53M | Buy |
10,357
+7,415
| +252% | +$1.1M | 0.05% | 152 |
|
2020
Q1 | $320K | Buy |
2,942
+300
| +11% | +$32.6K | 0.01% | 285 |
|
2019
Q4 | $303K | Buy |
2,642
+607
| +30% | +$69.6K | 0.01% | 371 |
|
2019
Q3 | $165K | Sell |
2,035
-73
| -3% | -$5.92K | 0.01% | 495 |
|
2019
Q2 | $150K | Buy |
2,108
+906
| +75% | +$64.5K | ﹤0.01% | 515 |
|
2019
Q1 | $112K | Buy |
1,202
+116
| +11% | +$10.8K | 0.01% | 485 |
|
2018
Q4 | $79K | Buy |
1,086
+147
| +16% | +$10.7K | ﹤0.01% | 520 |
|
2018
Q3 | $82K | Buy |
939
+98
| +12% | +$8.56K | ﹤0.01% | 531 |
|
2018
Q2 | $66 | Sell |
841
-528
| -39% | -$41 | ﹤0.01% | 387 |
|
2018
Q1 | $139K | Buy |
1,369
+170
| +14% | +$17.3K | 0.01% | 241 |
|
2017
Q4 | $158K | Buy |
1,199
+170
| +17% | +$22.4K | 0.01% | 218 |
|
2017
Q3 | $121K | Buy |
1,029
+85
| +9% | +$10K | 0.01% | 135 |
|
2017
Q2 | $75K | Buy |
+944
| New | +$75K | 0.01% | 206 |
|
2016
Q1 | $23K | Buy |
+450
| New | +$23K | 0.02% | 439 |
|